Radium 223 dichloride for prostate cancer treatment

Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo(®)) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Drug Des Devel Ther
Päätekijät: Deshayes, Emmanuel, Roumiguie, Mathieu, Thibault, Constance, Beuzeboc, Philippe, Cachin, Florent, Hennequin, Christophe, Huglo, Damien, Rozet, François, Kassab-Chahmi, Diana, Rebillard, Xavier, Houédé, Nadine
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2017
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5593411/
https://ncbi.nlm.nih.gov/pubmed/28919714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S122417
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia